Scholar Rock (NASDAQ:SRRK) Rating Reiterated by HC Wainwright

Scholar Rock (NASDAQ:SRRKGet Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $30.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 82.37% from the company’s current price.

Separately, Wedbush restated an “outperform” rating and issued a $23.00 target price on shares of Scholar Rock in a research note on Tuesday, January 23rd.

View Our Latest Research Report on Scholar Rock

Scholar Rock Trading Up 8.6 %

SRRK stock opened at $16.45 on Tuesday. The firm has a market cap of $1.19 billion, a PE ratio of -8.44 and a beta of 0.89. The firm has a fifty day moving average price of $15.55 and a 200 day moving average price of $12.98. Scholar Rock has a fifty-two week low of $5.56 and a fifty-two week high of $21.17. The company has a debt-to-equity ratio of 0.30, a quick ratio of 8.55 and a current ratio of 8.55.

Insider Transactions at Scholar Rock

In related news, insider Mo Qatanani sold 2,512 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.74, for a total value of $39,538.88. Following the transaction, the insider now owns 147,019 shares of the company’s stock, valued at $2,314,079.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Edward H. Myles sold 12,459 shares of the stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $18.83, for a total transaction of $234,602.97. Following the transaction, the chief financial officer now directly owns 168,784 shares in the company, valued at $3,178,202.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mo Qatanani sold 2,512 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.74, for a total value of $39,538.88. Following the completion of the transaction, the insider now owns 147,019 shares in the company, valued at $2,314,079.06. The disclosure for this sale can be found here. Insiders sold a total of 46,303 shares of company stock worth $769,490 over the last ninety days. Company insiders own 26.20% of the company’s stock.

Institutional Trading of Scholar Rock

Institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank boosted its holdings in shares of Scholar Rock by 15.5% in the 4th quarter. Amalgamated Bank now owns 4,869 shares of the company’s stock valued at $92,000 after buying an additional 652 shares during the period. Legal & General Group Plc raised its stake in shares of Scholar Rock by 8.1% during the 4th quarter. Legal & General Group Plc now owns 14,265 shares of the company’s stock worth $129,000 after purchasing an additional 1,072 shares in the last quarter. Alps Advisors Inc. increased its holdings in shares of Scholar Rock by 4.1% during the 3rd quarter. Alps Advisors Inc. now owns 41,535 shares of the company’s stock valued at $295,000 after acquiring an additional 1,628 shares during the last quarter. California State Teachers Retirement System boosted its stake in Scholar Rock by 4.2% during the 3rd quarter. California State Teachers Retirement System now owns 43,175 shares of the company’s stock valued at $307,000 after purchasing an additional 1,730 shares during the period. Finally, Rhumbline Advisers raised its holdings in Scholar Rock by 7.0% in the 1st quarter. Rhumbline Advisers now owns 29,405 shares of the company’s stock valued at $379,000 after acquiring an additional 1,918 shares in the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Company Profile

(Get Free Report)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Featured Stories

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.